Stay updated on TNO155 Combinations Clinical Trial
Sign up to get notified when there's something new on the TNO155 Combinations Clinical Trial page.

Latest updates to the TNO155 Combinations Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedLocations were updated to add sites in Massachusetts, New South Wales, Sichuan, Tokyo, Catalonia, and Valencia, with several previously listed locations removed; the page revision is updated to v3.3.3.SummaryDifference0.7%

- Check37 days agoChange DetectedStudy design, eligibility criteria, and listed locations are unchanged between the screenshots. Only user-interface layout changes and updated timestamps are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedA note clarifying that PubMed publications listed on the page may not be about the study. The revision number has been updated to v3.3.2.SummaryDifference0.2%

- Check58 days agoChange DetectedA general site-wide funding-status notice has been removed from the page.SummaryDifference0.4%

- Check72 days agoChange DetectedThe page continues to present the Phase Ib study details of TNO155 in combination with Spartalizumab or Ribociclib. Any observed changes are limited to administrative metadata, not the main study content.SummaryDifference0.4%

Stay in the know with updates to TNO155 Combinations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TNO155 Combinations Clinical Trial page.